Icariin-Mediated Inhibition of NF-κB Activity Enhances the In Vitro and In Vivo Antitumour Effect of 5-Fluorouracil in Colorectal Cancer

Cell Biochemistry and Biophysics

Volumn 69, Issue 3, 2014, Pages 523-530

  Shi, De Bing ^a   Li, Xin Xiang ^a   Zheng, Hong Tu ^a   Li, Da Wei ^a   Cai, Guo Xiang ^a   Peng, Jun Jie ^a   Gu, Wei Lie ^a   Guan, Zu Qing ^a   Xu, Ye ^a   Cai, San Jun ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

5 FU; Colorectal cancer; Combination therapy; Icariin; NF B

Indexed keywords

MURINAE;

ANTINEOPLASTIC AGENT; FLAVONOID; FLUOROURACIL; ICARIIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL TUMOR; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; FLAVONOIDS; FLUOROURACIL; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; NF-KAPPA B; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902381241     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-9827-5     Document Type: Article

References (48)

1. Ferlay, J., et al. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127(12), 2893-2917.
2. Jemal, A., et al. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2), 69-90.
3. Cunningham, D., et al. (2010). Colorectal cancer. Lancet, 375(9719), 1030-1047.
4. Jemal, A., et al. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59(4), 225-249.
5. Meyerhardt, J. A., & Mayer, R. J. (2005). Systemic therapy for colorectal cancer. New England Journal of Medicine, 352(5), 476-487.
6. Kuhn, J. G. (2001). Fluorouracil and the new oral fluorinated pyrimidines. Annals of Pharmacotherapy, 35(2), 217-227.
7. Benson, A. B, 3rd. (2006). New approaches to the adjuvant therapy of colon cancer. Oncologist, 11(9), 973-980.
8. Ohtsu, A. (2008). Chemotherapy for metastatic gastric cancer: Past, present, and future. Journal of Gastroenterology, 43(4), 256-264.
9. Chen, Y., et al. (2011). Icariin and its pharmaceutical efficacy: Research progress of molecular mechanism. Zhong Xi Yi Jie He Xue Bao, 9(11), 1179-1184.
10. Huang, X., Zhu, D., & Lou, Y. (2007). A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. European Journal of Pharmacology, 564(1-3), 26-36.
11. Li, S., et al. (2010). Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Letters, 298(2), 222-230.
12. Lin, C. C., et al. (2004). Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clinical and Experimental Pharmacology and Physiology, 31(1-2), 65-69.
13. Wang, Y., et al. (2010). Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. European Journal of Pharmacology, 635(1-3), 40-48.
14. Zhang, D. C., et al. (2013). Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-kappaB. Acta Pharmacologica Sinica, 34(2), 301-308.
15. Cheng, H., et al. (2011). In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines. Cancer Chemotherapy and Pharmacology, 67(3), 637-646.
16. Takada, Y., Khuri, F. R., & Aggarwal, B. B. (2004). Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. Journal of Biological Chemistry, 279(25), 26287-26299.
17. Kuo, Y. C., et al. (2012). Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-kappaB expression in vitro and in vivo. Biomedicine & Pharmacotherapy, 66(1), 12-20.
18. Csaki, C., et al. (2008). Regulation of inflammation signalling by resveratrol in human chondrocytes in vitro. Biochemical Pharmacology, 75(3), 677-687.
19. Buhrmann, C., et al. (2011). Curcumin modulates nuclear factor kappaB (NF-kappaB)-mediated inflammation in human tenocytes in vitro: Role of the phosphatidylinositol 3-kinase/Akt pathway. Journal of Biological Chemistry, 286(32), 28556-28566.
20. Huang, H., et al. (2011). Gambogic acid enhances proteasome inhibitor-induced anticancer activity. Cancer Letters, 301(2), 221-228.
21. Kim, S. L., et al. (2013). Synergistic antitumor effect of 5-fluorouracil in combination with parthenolide in human colorectal cancer. Cancer Letters, 335(2), 479-486.
22. Shakibaei, M., et al. (2013). Curcumin enhances the effect of chemotherapy against colorectal cancer cells by inhibition of NF-kappaB and Src protein kinase signaling pathways. PLoS One, 8(2), e57218.
23. Liu, T., et al. (2012). Effect of NF-kappaB inhibitors on the chemotherapy-induced apoptosis of the colon cancer cell line HT-29. Exp Ther Med, 4(4), 716-722.
24. Rath, P. C., & Aggarwal, B. B. (1999). TNF-induced signaling in apoptosis. Journal of Clinical Immunology, 19(6), 350-364.
25. Bostick, R. M., et al. (1994). Sugar, meat, and fat intake, and non-dietary risk factors for colon cancer incidence in Iowa women (United States). Cancer Causes and Control, 5(1), 38-52.
26. Poynter, J. N., et al. (2009). Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiology Biomarkers Prevention, 18(10), 2745-2750.
27. Leichman, C. G., et al. (2002). Biochemical modulation of 5-fluorouacil through dihydropyrimidine dehydrogenase inhibition: A Southwest Oncology Group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. Investigational New Drugs, 20(4), 419-424.
28. Levi, F. A., et al. (1994). Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. Journal of the National Cancer Institute, 86(21), 1608-1617.
29. Melen-Mucha, G., et al. (2004). Expression of p65 gene in experimental colon cancer under the influence of 5-fluorouracil given alone and in combination with hormonal modulation. Neoplasma, 51(4), 319-324.
30. Richards, F, 2nd, et al. (1986). Combination chemotherapy (5-fluorouracil, methyl-CCNU, mitomycin C) versus 5-fluorouracil alone for advanced previously untreated colorectal carcinoma. A phase III study of the Piedmont Oncology Association. Journal of Clinical Oncology, 4(4), 565-570.
31. Prete, S. P., et al. (2008). Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: Pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res, 27, 5.
32. Obi, S., et al. (2006). Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer, 106(9), 1990-1997.
33. Tong, J., et al. (2011). Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. Journal of Biomedicine and Biotechnology, 2011, 740564.
34. Kim, H. J., Hawke, N., & Baldwin, A. S. (2006). NF-kappaB and IKK as therapeutic targets in cancer. Cell Death and Differentiation, 13(5), 738-747.
35. Wang, Y. W., et al. (2012). Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in pancreatic cancer both in vitro and in vivo. Journal of Cancer Research and Clinical Oncology, 138(5), 785-797.
36. Sakamoto, K., et al. (2009). Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clinical Cancer Research, 15(7), 2248-2258.
37. Aggarwal, B. B. (2004). Nuclear factor-kappaB: The enemy within. Cancer Cell, 6(3), 203-208.
38. Wang, C. Y., et al. (1999). Control of inducible chemoresistance: Enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nature Medicine, 5(4), 412-417.
39. Bharti, A. C., & Aggarwal, B. B. (2002). Chemopreventive agents induce suppression of nuclear factor-kappaB leading to chemosensitization. Annals of the New York Academy of Sciences, 973, 392-395.
40. Baeuerle, P. A., & Baltimore, D. (1996). NF-kappa B: Ten years after. Cell, 87(1), 13-20.
41. Rayet, B., & Gelinas, C. (1999). Aberrant rel/nfkb genes and activity in human cancer. Oncogene, 18(49), 6938-6947.
42. Wang, F. X., et al. (2012). (3S)-1, 2, 3, 4-Tetrahydro-beta-carboline-3-carboxylic acid from Cichorium endivia. L induces apoptosis of human colorectal cancer HCT-8 cells. Molecules, 18(1), 418-429.
43. Kang, H. W., et al. (2012). Deguelin, an Akt inhibitor, down-regulates NF-kappaB signaling and induces apoptosis in colon cancer cells and inhibits tumor growth in mice. Digestive Diseases and Sciences, 57(11), 2873-2882.
44. Kunnumakkara, A. B., et al. (2008). Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clinical Cancer Research, 14(7), 2128-2136.
45. Sandur, S. K., et al. (2009). Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. International Journal of Radiation Oncology Biology Physics, 75(2), 534-542.
46. Guo, X., et al. (2010). Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Letters, 290(1), 104-113.
47. Jani, T. S., et al. (2010). Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. Journal of Biological Chemistry, 285(25), 19162-19172.
48. Horst, D., et al. (2009). Invasion associated up-regulation of nuclear factor kappaB target genes in colorectal cancer. Cancer, 115(21), 4946-4958.